7 Health Benefits of Metformin Beyond Blood Sugar — What the Research Shows

Metformin is a prescription medication used primarily to treat type 2 diabetes, but researchers have discovered that its effects may extend well beyond blood sugar control. By activating AMPK, a master regulator of cellular energy homeostasis, metformin influences pathways involved in aging, inflammation, cancer, cardiovascular health, and brain function.

Studies suggest these effects may help prevent or delay several age-related diseases. A 2025 review published in Cancers even described metformin as a “precision gerotherapeutic.” However, many of these benefits remain under investigation and are not currently approved indications for the drug.

Few medications have generated as much interest in longevity and healthy aging research as metformin. Originally developed to treat type 2 diabetes, metformin has been prescribed for decades because of its effectiveness, safety profile, and low cost. In recent years, researchers have had evidence suggesting metformin may offer benefits that extend beyond glucose control.

Studies have linked the drug to better heart health, lower cancer risk, improved metabolic function, and potential protection against age-related diseases. The FDA approved metformin for type 2 diabetes in the 1990s, but scientists continue to discover surprising effects that may influence how we think about aging and chronic disease.

It is important to note that metformin is a prescription medication. While research into its benefits beyond diabetes is exciting, these uses are still being studied and should only be considered under medical supervision.

Some of the benefits discussed below are supported by large observational studies and decades of clinical experience. Others remain promising areas of active investigation. Understanding the difference is essential when evaluating the evidence.

Read More: Diabetic Ketoacidosis (DKA): Symptoms, Causes, and When to Go to the ER

1. Reduced Cancer Risk

One of the most surprising discoveries in metformin research is its potential role in reducing cancer risk. A large body of research, including meta-analyses involving dozens of studies, has found that people taking metformin appear to have lower rates of several cancers, including gastrointestinal cancers, urologic cancers, and certain blood cancers.

Researchers believe several mechanisms may be involved. Metformin activates AMPK, which helps regulate cellular growth and energy use. This activation may reduce signals that encourage uncontrolled cell proliferation.

Metformin also lowers circulating insulin levels, which is important because insulin can promote tumor growth in some cancers. In addition, the drug appears to have anti-inflammatory effects that may make the tumor environment less favorable for cancer development.

A 2025 review in Cancers concluded that clinical data now support metformin’s ability to reduce cancer incidence and improve outcomes in some settings. Researchers are also studying whether combining metformin with traditional cancer therapies may provide additional benefits.

Evidence Grade: Strong observational evidence across multiple cancer types. Clinical trials are ongoing, and cancer prevention is not currently an approved indication for metformin.

2. Cardiovascular Protection

Heart disease remains the leading cause of death worldwide, making metformin’s cardiovascular effects especially important. Research suggests metformin can improve cardiovascular outcomes and reduce the risk of cardiovascular death in people with type 2 diabetes.

The medication lowers LDL cholesterol and triglycerides, improves endothelial function, reduces platelet aggregation, and supports healthy blood vessel function. AMPK activation also appears to have direct protective effects on cardiac muscle. Scientists believe these actions help explain why metformin’s benefits extend beyond glucose management.

The landmark UK Prospective Diabetes Study (UKPDS) demonstrated cardiovascular benefits in people with type 2 diabetes decades ago, and subsequent research has reinforced these findings.

Evidence Grade: Strong. Cardiovascular protection is one of metformin’s most established non-glycemic benefits.

3. Potential Protection Against Dementia and Cognitive Decline

Researchers are increasingly interested in the relationship between metabolic health and brain health. Several observational studies have found lower rates of dementia and mild cognitive impairment among people with type 2 diabetes who take metformin.

Some evidence also suggests the medication may reduce the risk of Alzheimer’s disease. Scientists believe metformin may help by reducing neuroinflammation, improving insulin sensitivity in the brain, and supporting mitochondrial function.

Brain insulin resistance is increasingly recognized as a contributor to Alzheimer’s disease, making metformin’s metabolic effects particularly interesting. AMPK activation may also help reduce oxidative stress and improve neuronal energy balance, both of which play roles in healthy cognitive aging.

Evidence Grade: Promising but not proven. Observational data and biological mechanisms are encouraging, but randomized trials specifically designed to evaluate cognitive outcomes are still needed.

4. Biological Aging and Longevity — The Most Exciting and Most Uncertain

Perhaps the most ambitious question surrounding metformin is whether it can slow biological aging itself. This idea is no longer confined to science fiction. It is now the subject of major research programs, including NIH-supported investigations.

A 2024 study published in Cell found that metformin slowed biological aging clocks in male monkeys, providing the first primate evidence that the drug may directly influence aging processes.

Researchers have also reported evidence that metformin can slow biological age markers in human studies. These findings suggest the drug may affect underlying mechanisms involved in aging rather than targeting a single disease.

The most anticipated study in this area is the TAME trial, short for Targeting Aging with Metformin. The trial is designed to determine whether metformin can delay the onset of multiple age-related diseases in adults without diabetes. If successful, it could reshape how medicine approaches aging itself.

Evidence Grade: Highly promising but still uncertain. The biological aging data are exciting, but the TAME trial has not yet reported primary outcomes. Metformin should not currently be viewed as a proven anti-aging treatment.

Read More: Diabetes in the Elderly: Unique Challenges, Medication Risks, and Care Goals

5. PCOS Management Beyond Ovulation

Metformin is widely used for polycystic ovary syndrome (PCOS), even though the condition is not diabetes. Many women with PCOS have underlying insulin resistance that contributes to elevated androgen levels.

These hormonal changes can lead to irregular menstrual cycles, acne, excess hair growth, and fertility challenges. By improving insulin sensitivity, metformin addresses one of the root drivers of PCOS.

Research consistently shows improvements in menstrual regularity, androgen levels, and metabolic markers among women using the medication. Metformin is often used alongside lifestyle changes and may be especially helpful for women who do not achieve adequate results through diet and exercise alone.

Evidence Grade: Well established. Multiple systematic reviews and clinical guidelines support metformin as an evidence-based option for PCOS management.

6. Weight and Appetite Regulation

Although metformin is not primarily a weight-loss medication, it can support modest reductions in body weight.

Many users experience decreased appetite after starting treatment. Researchers believe this effect may involve several pathways, including GLP-1 stimulation, AMPK-mediated appetite regulation, and changes in gut function that influence calorie absorption. Weight loss with metformin is generally modest, averaging about 2 to 4 kilograms over a year.

While this is significantly less than what is typically seen with newer GLP-1 receptor agonists such as semaglutide or tirzepatide, it can still provide meaningful health benefits. The medication may be particularly useful for individuals with insulin resistance and for women with PCOS who struggle with weight management.

Evidence Grade: Well established for modest weight reduction and appetite regulation in people with insulin resistance and type 2 diabetes.

7. Gut Microbiome Health

Scientists now recognize that some of metformin’s benefits may originate in the gut. Research shows the medication changes the composition of the gut microbiome, increasing beneficial bacteria such as Akkermansia muciniphila. This organism is associated with stronger gut barrier function and better metabolic health.

Metformin also appears to reduce the abundance of certain pro-inflammatory bacteria while promoting microbial communities associated with improved glucose regulation.

These microbial changes may contribute to the drug’s broader effects on metabolism, inflammation, and overall health. Researchers are actively studying whether the gut microbiome serves as a key mediator of many of metformin’s benefits.

Evidence Grade: Emerging. The microbiome effects are well documented, but researchers are still determining how much they contribute to long-term clinical outcomes.

The Side Effects and Considerations That Matter

Metformin’s benefits must be considered alongside its limitations. The most common side effects are gastrointestinal. Nausea, diarrhea, bloating, and abdominal discomfort affect roughly 25% of people when treatment begins. These symptoms often improve over time, and extended-release formulations significantly reduce the risk.

Another important concern is vitamin B12 deficiency. Long-term metformin use can reduce B12 absorption in the ileum, increasing the risk of deficiency that may go unnoticed for years. Annual B12 monitoring is recommended for long-term users, although this is not always routinely performed.

Metformin is also contraindicated in people with significant kidney impairment, particularly when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m², due to the risk of lactic acidosis. Regular kidney function monitoring remains standard practice.

Read More: Evidence: How Reversing Prediabetes Affects Heart Health

Conclusion

Metformin activates AMPK, a master regulator of cellular energy homeostasis, and that activation appears to influence far more than blood sugar levels. Research supports benefits ranging from cardiovascular protection and cancer risk reduction to potential effects on aging and cognitive health.

Some findings are already well established, while others remain active areas of investigation. Metformin is a prescription medication that requires medical oversight. It is not a wellness supplement, and its most exciting applications are still being tested in clinical trials.

Frequently Asked Questions

Q. Can you take metformin if you don’t have diabetes?

Metformin is a prescription medication and should only be taken under a doctor’s supervision. Researchers are studying its benefits in people without diabetes, including through the TAME trial, but it is not approved as an anti-aging drug.

Q. Does metformin slow aging?

The evidence is promising but not definitive. A 2024 study published in Cellfound that metformin slowed biological aging clocks in monkeys, and human aging-clock studies are also emerging. The TAME trial is specifically designed to determine whether metformin delays age-related diseases in adults without diabetes.

Q. What are the downsides of taking metformin long-term?

The most important long-term concerns are vitamin B12 deficiency and gastrointestinal side effects. Metformin can impair B12 absorption, making annual monitoring important for long-term users. Digestive symptoms affect about one-quarter of users but are often improved with extended-release formulations. Kidney function must be monitored.